PDCD4 and breast carcinoma: Additionally, Gonzalez-Ortiz et al. [72] demonstrated that Pdcd4 expression is downregulated in doxorubicin-resistant MDA-MB-231 breast cancer cells, which subsequently reduces the interaction of Pdcd4 and eIF4A, implying that eIF4A downstream targets are involved in doxorubicin resistance.